GSK to shut down Medicines Research Unit

GSK will cease operation of its research unit at Sydney's Prince of Wales Hospital at the end of the month, laying off eight employees and five contractors.

Pharmaxis to take anti-inflammatory to human trials

Pharmaxis (ASX:PXS) plans to conduct the first human trials of PXS4728A - a drug candidate for inflammatory diseases including COPD and NASH - in 1Q15.

PAP therapy saves lives in heart patients: ResMed

Positive airway pressure (PAP) therapy in heart patients with sleep apnoea can reduce mortality rates by up to 38%, analysis from ResMed (ASX:RMD) suggests.

Australia's medical research sector advocates for the Medical Research Future Fund

​The newly formed Medical Research Future Fund (MRFF) Action Group is advocating for what it claims to be the most important initiative in Australian medical research in generations.

GI Dynamics lines up new CEO

Seasoned medical device executive Michael Dale will take over from Stuart A Randle as CEO of GI Dynamics (ASX:GID) from next month.

Phylogica awarded three new peptide patents

Phylogica (ASX:PYC) has added a Japanese patent and two more from the US to its intellectual property portfolio.

AusBiotech welcomes Greens' push for quarterly payments on R&D Tax Incentive

AusBiotech fully supports the Australian Greens' moving of an amendment in the Senate to put in place quarterly payments for small and medium-size businesses eligible for an R&D Tax Incentive refund.

AFL approves use of Regeneus's HiQCell

The AFL has added Regeneus (ASX:RGS) HiQCell to a list of approved treatments for injuries including impact-related osteoarthritis and tendonitis.

Mesoblast posts wider loss, details product roadmap

Mesoblast (ASX:MSB) has announced its financial results for FY14 and laid out a five-pronged strategy for commercialising its key regenerative medicine products.

Vaxxas recognised by WEF for vaccine tech

Vaxxas has been selected as a 2015 Technology Pioneer by the World Economic Forum for its patch-based vaccine delivery technology.

ResMed scores initial win in ITC case against BMC

A US ITC judge has found in favour of ResMed (ASX:RMD) in the company's patent infringement action against China's BMC Medical, and has recommended an import ban.

Tech Transfer Summit set to be held next week in Adelaide

Following on from a successful first-ever Tech Transfer Summit (TTS) Australia in 2013, the TTS Global Initiative and AusBiotech are pleased to confirm the Australian chapter will be returning to South Australia next week with the support of major partner BioSA.

Alchemia, Mesoblast hire new CFOs

Former Mesoblast (ASX:MSB) CFO Jenni Pilcher has joined Alchemia (ASX:ACL), while former Novartis ANZ CFO 

Paul Hodgkinson will fill the vacant position at Mesoblast.

Orthocell aces tennis elbow trial

Orthocell's (ASX:OCC) autologous cell therapy Ortho-ATI improved grip strength in chronic tennis elbow patients by an average of 207% at 4.5 years post-treatment.

Consultation begins for new Industry Skills Fund

The federal government's new $476 million Industry Skills Fund is due to commence 1 January 2015 and a consultation has commenced in preparation, which includes webinars, a discussion paper and a digital questionnaire.